Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.36 |
| ▸ | ITGAL | P20701 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | CRHBP | P24387 | 2/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626503 | 0.75 | CA2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL1079302 | 0.69 | NISCH (0.48) | ABCG2ITGB2ICAM1ITGALNISCH | |
| SCHEMBL17969038 | 0.69 | CA2 (0.32) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL7765721 | 0.69 | HRH3 (0.34) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL3639081 | 0.69 | CA2 (0.45) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL3072276 | 0.69 | MAOA (0.46) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL11307666 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL8525523 | 0.69 | POLB (0.43) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL329533 | 0.69 | ABCG2 (0.36) | ABCG2ITGB2ICAM1ITGALCA2 | |
| SCHEMBL329447 | 0.69 | MAOA (0.46) | ABCG2ITGB2ICAM1ITGALCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| WO-2023055427-A1 | SMALL MOLECULE ANTAGONISTS OF PF4 | NEW YORK BLOOD CENTER, INC. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | claimed |
| CN-112654354-A | 1,3,4, 9-tetrahydro-2H-pyrido [3,4-b ] indole derivative compound and application thereof | 菲尼克思药业股份有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3703747-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2020-09-09 | — | — | EP | claimed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| EP-3479843-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | GenKyoTex Suisse SA (CH) | 2019-05-08 | — | — | EP | claimed |
| EP-2758051-B1 | CYANOMETHYLPYRAZOLE CARBOXAMIDES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | claimed |
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2016-10-06 | — | — | US | claimed |
| EP-3068778-A2 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | The University of Kansas (US) | 2016-09-21 | — | — | EP | claimed |
| EP-0956286-B1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR INC (US) | 2003-04-02 | — | — | EP | claimed |
| WO-2003009847-A1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM, INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2003009850-A1 | SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEN INC. (US) | 2003-02-06 | — | — | WO | claimed |
| WO-2001091558-A1 | HERBICIDAL AGENTS BASED ON SUBSTITUTED CARBOXAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2001-12-06 | — | — | WO | claimed |
| EP-0956286-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1999-11-17 | — | — | EP | claimed |
| US-5925761-A | Synthesis of terfenadine and derivatives | SEPRACOR INC. (US) | 1999-07-20 | — | — | US | claimed |
| WO-1998033789-A1 | SYNTHESIS OF TERFENADINE AND DERIVATIVES | SEPRACOR, INC. (US) | 1998-08-06 | — | — | WO | claimed |
| EP-0505540-A4 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | — | 1992-10-28 | — | — | EP | claimed |
| EP-0505540-A1 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | MCNEILAB, INC. (US) | 1992-09-30 | — | — | EP | claimed |
| WO-1992005152-A2 | PROCESS FOR PRODUCING POLYHYDROXYLATED PIPERIDINES AND PYRROLIDINES AND COMPOUNDS THEREOF | MCNEILAB, INC. (US) | 1992-04-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289217-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | ABCG2 1141/4885ITGB2 4485/4885ICAM1 3038/4885 |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | ABCG2 4511/4885ITGB2 1696/4885ICAM1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.